Wei Shen Tan, MD, PhD
Assistant ProfessorDownloadHi-Res Photo
Cards
Appointments
Urology
Primary
Training
Fellow, Urologic Oncology
University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Fellow, Robotic Urology
University College London Hospitals
University College London Hospitals
Publications Overview
- 181 Publications
- 2,479 Citations
- 1 Yale Co-Author
Appointments
Urology
Primary
Training
Fellow, Urologic Oncology
University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Fellow, Robotic Urology
University College London Hospitals
University College London Hospitals
Publications Overview
- 181 Publications
- 2,479 Citations
- 1 Yale Co-Author
Appointments
Urology
Primary
Training
Fellow, Urologic Oncology
University of Texas MD Anderson Cancer Center
University of Texas MD Anderson Cancer Center
Fellow, Robotic Urology
University College London Hospitals
University College London Hospitals
Publications Overview
- 181 Publications
- 2,479 Citations
- 1 Yale Co-Author
About
Titles
Assistant Professor
Biography
Wei Shen Tan, MD, PhD, FRCS is a urologic oncologist with expertise in the treatment of bladder, prostate and kidney cancers. He completed his Society of Urologic Oncology (SUO)-accredited fellowship at the prestigious University of Texas MD Anderson Cancer Center, Houston, TX and a robotic urology fellowship at University College London Hospital, London, UK. Dr. Tan completed his urology residency through the London School of Surgery and is a Fellow of the Royal College of Surgeons of England.
Dr. Tan holds a PhD in Uro-oncology, with his research focusing on genitourinary cancers. His key interests include: 1) Cancer diagnostics, 2) Novel treatments for bladder cancer, 3) Biomarker development for bladder cancer, 4) Characterization of non-muscle-invasive bladder cancer and 5) Optimizing perioperative outcomes following radical cystectomy through enhanced recovery protocols and robotic surgery.
He is a co-investigator in several major clinical trials, including DETECT I & II, HYMN, BOXIT, and HIVEC-II. His work has resulted in over 100 peer-reviewed publications. Dr. Tan also serves on the editorial boards of the British Journal of Urology International and the Journal of Men’s Health.
Appointments
Education & Training
- Fellow, Urologic Oncology
- University of Texas MD Anderson Cancer Center
- Fellow, Robotic Urology
- University College London Hospitals
- Resident, Urology
- London School of Surgery
- Non Degree Program
- Royal College of Surgeons of England
- PhD
- University College London
- MD
- Cardiff University
- BSc
- University College London
Research
Overview
Medical Subject Headings (MeSH)
Non-Muscle Invasive Bladder Neoplasms; Transurethral Resection of Bladder; Urinary Bladder Neoplasms
ORCID
0000-0002-6119-4043
Research at a Glance
Publications Timeline
A big-picture view of Wei Shen Tan's research output by year.
Research Interests
Research topics Wei Shen Tan is interested in exploring.
181Publications
2,479Citations
Urinary Bladder Neoplasms
Non-Muscle Invasive Bladder Neoplasms
Transurethral Resection of Bladder
Publications
2024
Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer
Taylor J, Kamat A, O'Donnell M, Annapureddy D, Howard J, Tan W, McElree I, Davaro F, Yim K, Harrington S, Dyer E, Black A, Kanabur P, Roumiguié M, Lerner S, Black P, Raman J, Preston M, Steinberg G, Huang W, Li R, Packiam V, Woldu S, Lotan Y. Long‐term outcomes of bladder‐sparing therapy vs radical cystectomy in BCG‐unresponsive non‐muscle‐invasive bladder cancer. BJU International 2024 PMID: 39183466, DOI: 10.1111/bju.16509.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBladder-sparing therapyUpfront RCRadical cystectomyCohort of patientsBladder cancerBCG-unresponsive NMIBCRetrospective cohort of patientsProgression to MIBCUpfront radical cystectomyCancer-specific survivalInstitutional review board approvalMetastasis-free survivalFood and Drug Administration criteriaRate of recurrenceReview board approvalLong-term outcomesStatistically significant differenceNodal diseaseRe-resectionSystemic immunotherapyIntravesical chemotherapyOncological outcomesOverall survivalOncological riskBladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection
Li R, Hensley P, Gupta S, Al-Ahmadie H, Babjuk M, Black P, Brausi M, Bree K, Fernández M, Guo C, Horowitz A, Lamm D, Lerner S, Lotan Y, Mariappan P, McConkey D, Mertens L, Mir C, Ross J, O'Donnell M, Palou J, Pohar K, Steinberg G, Soloway M, Spiess P, Svatek R, Tan W, Taoka R, Buckley R, Kamat A. Bladder-sparing Therapy for Bacillus Calmette-Guérin–unresponsive Non–muscle-invasive Bladder Cancer: International Bladder Cancer Group Recommendations for Optimal Sequencing and Patient Selection. European Urology 2024 PMID: 39183090, DOI: 10.1016/j.eururo.2024.08.001.Peer-Reviewed Original ResearchAltmetricConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder-sparing treatmentCarcinoma in situNadofaragene firadenovecRadical cystectomyBladder cancerOptimal selection of patientsAbsence of randomized trialsBladder-sparing therapySingle-agent chemotherapyBladder cancer groupSelection of patientsDevelopment of agentsPatient selectionSystemic toxicityCancer groupUnapproved agentsClinical trial participationPatient characteristicsRandomized trialsMitomycin CTumor attributesConsensus recommendationsCancer expertsChallenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. Challenging the Paradigm of “BCG-unresponsive” Bladder Cancer: Does Additional Bacillus Calmette-Guérin Have an Effect? European Urology 2024 PMID: 38879371, DOI: 10.1016/j.eururo.2024.05.027.Peer-Reviewed Original ResearchAltmetricMale Robot-Assisted Radical Cystectomy with Nerve Sparing Technique
Tan W, Ta A, Sridhar A, Kelly J. Male Robot-Assisted Radical Cystectomy with Nerve Sparing Technique. 2024, 291-302. DOI: 10.1007/978-3-031-49428-4_23.Peer-Reviewed Original ResearchHematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria
Tan W, Ahmad A, Zhou Y, Nathan A, Ogunbo A, Gbolahan O, Kallam N, Smith R, Khalifeh M, Tan W, Cohen D, Volanis D, Walter F, Sasieni P, Kamat A, Kelly J. Hematuria Cancer Risk Score with Ultrasound Informs Cystoscopy Use in Patients with Hematuria. European Urology Oncology 2024 PMID: 38811250, DOI: 10.1016/j.euo.2024.05.005.Peer-Reviewed Original ResearchAltmetricConceptsCancer risk scoreRenal bladder ultrasoundTa bladder cancerUrinary tract cancerRisk scoreValidation cohortBladder cancerHealth care cost savingsBladder ultrasoundDiagnosis of urinary tract cancerInvasive proceduresDevelopment cohortIdentification of cancerSuspicion of bladder cancerSecondary careIndependent validation cohortReceiver operating characteristic curveUK hospitalsArea under the receiver operating characteristic curveOutcome measuresTriage of patientsConsecutive patientsPatient cohortCystoscopyHematuriaMP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE
Tan W, Contieri R, Buffi N, Lughezzani G, Grajales V, Soloway M, Casale P, Hurle R, Kamat A. MP16-06 THE INTERNATIONAL BLADDER CANCER GROUP INTERMEDIATE-RISK NON-MUSCLE INVASIVE BLADDER CANCER (IBCG IR-NMIBC) SCORING SYSTEM PREDICTS THE NEED FOR INTERVENTION FOR PATIENTS ON ACTIVE SURVEILLANCE. Journal Of Urology 2024, 211: e241. DOI: 10.1097/01.ju.0001008640.01272.9d.06.Peer-Reviewed Original ResearchMP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT?
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. MP16-08 CHALLENGING THE PARADIGM OF “BCG UNRESPONSIVE” BLADDER CANCER: DOES ADDITIONAL BCG HAVE AN EFFECT? Journal Of Urology 2024, 211: e242. DOI: 10.1097/01.ju.0001008640.01272.9d.08.Peer-Reviewed Original ResearchConceptsPD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN
Myers A, Tan W, Grajales V, Hwang H, Bree K, Navai N, Lee B, Dinney C, Kamat A. PD30-08 ELUCIDATING THE RESPONSE RATES TO CONTINUED BACILLUS CALMETTE-GUERIN (BCG) IN PATIENTS WITH BCG EXPOSED BLADDER CANCER: IMPLICATIONS FOR CLINICAL TRIAL DESIGN. Journal Of Urology 2024, 211: e627. DOI: 10.1097/01.ju.0001008848.77629.6f.08.Peer-Reviewed Original ResearchConceptsMP24-20 IMPACT OF MENTAL HEALTH ILLNESS ON ADHERENCE TO SURVEILLANCE AND TREATMENT GUIDELINES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS
Grajales V, Duan Z, Tan W, Contieri R, Myers A, Zhao H, Giordano S, Williams S, Kamat A. MP24-20 IMPACT OF MENTAL HEALTH ILLNESS ON ADHERENCE TO SURVEILLANCE AND TREATMENT GUIDELINES IN NON-MUSCLE INVASIVE BLADDER CANCER PATIENTS. Journal Of Urology 2024, 211: e401. DOI: 10.1097/01.ju.0001008860.46052.c4.20.Peer-Reviewed Original ResearchMP35-06 PICTURE PERFECT DIAGNOSES: EVALUATING UROLOGISTS' TUMOR IDENTIFICATION SKILLS: THE PROSPECTIVE TUMOR GRADING VISUAL ACCURACY (TRIVIA) STUDY
Grajales V, Contieri R, Tan W, Tuke D, Akhverdiyeva L, Hwang H, Myers A, Kamat A. MP35-06 PICTURE PERFECT DIAGNOSES: EVALUATING UROLOGISTS' TUMOR IDENTIFICATION SKILLS: THE PROSPECTIVE TUMOR GRADING VISUAL ACCURACY (TRIVIA) STUDY. Journal Of Urology 2024, 211: e582. DOI: 10.1097/01.ju.0001009372.61513.54.06.Peer-Reviewed Original Research
Clinical Care
Overview
Clinical Specialties
Urology
Fact Sheets
Bladder Cancer
Learn More on Yale MedicineProstate Cancer
Learn More on Yale MedicineKidney Cancer
Learn More on Yale Medicine
Board Certifications
Urology
- Certification Organization
- Royal College of Surgeons of England
- Original Certification Date
- 2022
Yale Medicine News
Are You a Patient?
View this doctor's clinical profile on the Yale Medicine website for information about the services we offer and making an appointment.
View Doctor ProfileLinks
Related Links
Get In Touch
Contacts
Email
Appointment Number
Mailing Address
Yale Medicine
789 Howard St, FMP 315
New Haven, CT 06519
United States